Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IndustryARC | PRODUCT CODE: 1075885

Cover Image

PUBLISHER: IndustryARC | PRODUCT CODE: 1075885

H1N1 Vaccine Market - Forecast(2022 - 2027)

PUBLISHED:
PAGES: 124 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Corporate License)
USD 6900

Add to Cart

H1N1 Vaccine Market size is forecast to reach $2.3 billion by 2027, growing at a CAGR of 4.51% during the forecast period 2022-2027. H1N1 influenza virus or swine H1N1 virus is a causative agent of infectious disease caused in human beings known as H1N1 or commonly referred to as swine flu. The H1N1 virus mainly affects the respiratory system including the nose, lungs, and throat of the infected person. Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population are the major factors driving the growth of the market. Innovation in vaccine manufacturing to obtain universally acceptable vaccine for the H1N1 virus and increased awareness on H1N1 influenza is set to further enhance the overall market demand for H1N1 Vaccine Market during the forecast period 2022-2027.

H1N1 Vaccine Market Report Coverage

The report: "H1N1 Vaccine Market Forecast (2022-2027)", by IndustryARC, covers an in-depth analysis of the following segments of the H1N1 Vaccine Market.

By Vaccine Type: Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccines, Intramuscular, and Toxoid

By Type of Brand: Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip, and Others

By Geography: North America, Europe, Asia Pacific and Rest of the World (RoW)

Key Takeaways

North America dominated the H1N1 Vaccine Market in 2019 owing to the increasing initiatives for the prevention of H1N1 infection and technological advancements in the vaccine's presence of well-established healthcare infrastructure. The H1N1 Vaccine Market scope for different regions will be provided in the final report.

Rising vaccine manufacturing technologies and improved profitability for the industry are likely to aid in the market growth of the H1N1 Vaccine Market.

Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the H1N1 Vaccine Market report.

Stringent regulatory rules and the absence of experienced medical professionals is poised to create hurdles for the H1N1 Vaccine Market.

H1N1 Vaccine Market Segment Analysis - By Vaccine Type

The Intramuscular held the largest share in the H1N1 Vaccine Market in 2019 and is estimated to grow at a CAGR of 5.19% during the forecast period 2022-2027. An intramuscular injection is a procedure used to deliver a medication deep into the muscles which allow the medication to be absorbed into the bloodstream quickly. Intramuscular injections are absorbed faster than subcutaneous injections owing to the fact that muscles have a greater blood supply than the tissue present under the skin. Moreover, muscle tissue can also hold a larger volume of medication than subcutaneous tissue. Intramuscular injections are a common practice in modern medicine. They're used to deliver drugs and vaccines. Several drugs and almost all injectable vaccines are delivered this way. Intramuscular injections are used when other types of delivery methods aren't recommended. Intramuscular injections are absorbed faster than subcutaneous injections since muscle tissue has a greater blood supply than the tissue just under the skin. Muscle tissue can also hold a larger volume of medication than subcutaneous tissue. Oral and Intramuscular vaccination has been considered to date as the ultimate way, but the nasal route offers advantages such as ease of self-administration and induction of mucosal as well as systemic immunity. Both liquid and dry powder formulations can be given via the intranasal route. Great consideration has to be given while selecting a suitable device for nasal administration since the volume delivered is very low. Several devices are available based on the number of doses to be administered and the type of dosage formulation Intramuscular is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2022-2027.

H1N1 Vaccine Market Segment Analysis - By Geography

North America dominated the H1N1 Vaccine Market in 2019 with a share of more than 38.97%, followed by the Asia Pacific owing to increasing awareness among the masses about the diseases coupled with growing government initiatives and programs to raise awareness among people about various infectious diseases.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2022-2027 owing to the discovery of new vaccines with greater efficiency, and advancements in the field of biomedical science. Increasing awareness among people about preventable diseases, the government launched programs to eradicate such infectious diseases and their causes, low wages to be paid to the workers, availability of a large talent pool and skilled personnel and less stringent environment and health safety regulations is also increasing the growth of the H1N1 vaccine market in this region.

H1N1 Vaccine Market Drivers

Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population

Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population is increasing the growth of the H1N1 Vaccine Market. Flu virus known as H1N1 is a combination of viruses from pigs, birds, and humans. H1N1 caused respiratory infection in humans that was commonly referred to as swine flu. Influenza virus causes acute upper and lower respiratory infections and is the most likely, among known pathogens, to cause a large epidemic in humans. The influenza virus mutates rapidly, enabling it to evade natural and vaccine-induced immunity. Furthermore, influenza viruses can cross from animals to humans, generating novel, potentially pandemic strains. Currently, available influenza vaccines induce a strain-specific response and might be ineffective against new influenza viruses. The difficulty in predicting circulating strains has frequently resulted in a mismatch between the annual vaccine and circulating viruses. Influenza viruses circulate globally and affect all age groups. Vaccines are the best tools available for preventing influenza illness. Thus, increasing the growth of the H1N1 Vaccine Market during the forecast period 2022-2027.

Innovation in vaccine manufacturing to obtain the universally acceptable vaccine for H1N1 virus and increased awareness on H1N1 influenza

Innovation in vaccine manufacturing to obtain the universally acceptable vaccine for the H1N1 virus and increased awareness of H1N1 influenza is increasing the growth of the H1N1 Vaccine Market. Several new technologies and associated tools have the potential to revolutionize influenza surveillance and response activities. These include the increasingly routine use of whole-genome next-generation sequencing and other high-throughput approaches. Such approaches could not only become key elements in outbreak investigations but could drive a new surveillance paradigm. However, despite the advances made, significant challenges need to be addressed before next-generation technologies become routine, particularly in low-resource settings. Strengthening the vaccine virus selection process additionally requires the continuation of initiatives to improve the timeliness and representativeness of influenza viruses. Emerging approaches and techniques such as synthetic genomics, systems genetics, systems biology, and mathematical modelling are capable of generating potentially huge volumes of highly complex and diverse datasets. Growing awareness of influenza as an important global public health issue has been coupled to ever-increasing demands from the global community for more equitable access to effective and affordable influenza vaccines. The current influenza vaccine landscape continues to be dominated by egg-based inactivated and live attenuated vaccines, with a small number of cell-based and recombinant vaccines. Thus, increasing the growth of the H1N1 Vaccine Market during the forecast period 2022-2027.

H1N1 Vaccine Market Challenges

Stringent regulatory rules and the absence of experienced medical professionals

Some of the factors that can impede the growth of the H1N1 Vaccine Market are stringent regulatory rules and the absence of experienced medical professionals. The high capital requirement, ample production to meet the population demand is set to create hurdles for the H1N1 vaccine market.

H1N1 Vaccine Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the H1N1 Vaccine Market. In 2019, the H1N1 Vaccine Market share is consolidated by the top ten players present in the market. H1N1 Vaccine, the top 10 companies are Abbott Laboratories, Pfizer, CPL Biologicals, Zydus Cadila, CSL Limited, Mitsubishi Tanabe Pharma Corporation, Glaxosmith, Commonwealth Serum Laboratories, Sinobac, and Astra Zeneca Plc. among others.

Acquisitions/Product Launches

In April 2016, Abbott Laboratories acquired St. Jude Medical for $25Bn.

Product Code: HCR 0129

Table of Contents

1. H1N1 Vaccine Market - Overview

  • 1.1 Definitions and Scope

2. H1N1 Vaccine Market - Executive Summary

  • 2.1 Market Revenue and Key Trends by Company
  • 2.2 Key trends by Vaccine Type
  • 2.3 Key trends by Type of Brand
  • 2.4 Key trends by Geography

3. H1N1 Vaccine Market - Comparative Analysis

  • 3.1 Product Benchmarking - Key Companies
  • 3.2 Financial Analysis - Key Companies
  • 3.3 Market Value Split by Key Companies
  • 3.4 Patent Analysis - Key Companies
  • 3.5 Pricing Analysis

4. H1N1 Vaccine Market Forces

  • 4.1 Market Drivers
  • 4.2 Market Constraints/Challenges
  • 4.3 Porters five force model
    • 4.3.1 Bargaining power of suppliers
    • 4.3.2 Bargaining powers of customers
    • 4.3.3 Threat of new entrants
    • 4.3.4 Rivalry among existing players
    • 4.3.5 Threat of substitutes

5. H1N1 Vaccine Market - Strategic Analysis

  • 5.1 Value Chain Analysis
  • 5.2 Opportunities Analysis
  • 5.3 Market Life Cycle

6. H1N1 Vaccine Market - By Vaccine Type (Market Size -$Million/$Billion)

  • 6.1 Intranasal
  • 6.2 Conjugate
  • 6.3 Attenuated Vaccines
  • 6.4 Inactivated Vaccine
  • 6.5 Intramuscular
  • 6.6 Toxoid
  • 6.7 Others

7. H1N1 Vaccine Market - By Type of Brand (Market Size -$Million/$Billion)

  • 7.1 Agripal
  • 7.2 Fiuarix
  • 7.3 Influgen
  • 7.4 Influvac
  • 7.5 Nasovac
  • 7.6 Vaxigrip
  • 7.7 Other

8. H1N1 Vaccine Market - By Geography

  • 8.1 North America
    • 8.1.1 U.S.
    • 8.1.2 Mexico
    • 8.1.3 Canada
  • 8.2 Europe
    • 8.2.1 U.K.
    • 8.2.2 France
    • 8.2.3 Germany
    • 8.2.4 Italy
    • 8.2.5 Spain
    • 8.2.6 Rest of Europe
  • 8.3 Asia Pacific
    • 8.3.1 China
    • 8.3.2 India
    • 8.3.3 Japan
    • 8.3.4 South Korea
    • 8.3.5 Australia
    • 8.3.6 New Zealand
    • 8.3.7 Rest of APAC
  • 8.4 Rest of the World
    • 8.4.1 Middle East
    • 8.4.2 Africa
    • 8.4.3 South America

9. H1N1 Vaccine Market - Entropy

10. H1N1 Vaccine Market Company Analysis

  • 10.1 Company 1
  • 10.2 Company 2
  • 10.3 Company 3
  • 10.4 Company 4
  • 10.5 Company 5
  • 10.6 Company 6
  • 10.7 Company 7
  • 10.8 Company 8
  • 10.9 Company 9
  • 10.10 Company 10

"*Financials for private companies would be provided on a best efforts basis".

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!